688506 Sichuan Biokin Pharmaceutical

Sichuan Biokin Pharma Gets Nod for Trial of Two Drugs

02:59 AM EDT, 03/23/2023 (MT Newswires) -- Sichuan Biokin Pharmaceutical (SHA:688506) will hold clinical trials into two drugs after obtaining approval from China's National Medical Products Administr

03-23 15:01

Combinations related to Bailey Tianheng (688506.SH)'s innovative biopharmaceuticals BL-B01D1 and SI-B003 were approved for clinical trials

According to the Zhitong Finance App, Bailey Tianheng (688506.SH) announced that the combination drugs “BL-B01D1+ chemotherapy” and “BL-B01D1+SI-B003± chemotherapy” related to the innovative biopharmaceuticals BL-B01D1 and SI-B003 developed independently by the company have recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the China Drug Administration (NMPA). Relevant clinical trials were: Evaluating that BL-B01D1 combined chemotherapy (BL-B01D1+ chemotherapy) and BL-B01D1+SI-B003 were not combined or combined

03-21 19:16

Bailey Tianheng: Innovative biopharmaceutical approved for phase II clinical trial

03-21 19:05

Bailey Tianheng: “BL-B01D1+ Chemotherapy” and “BL-B01D1 SI-B003± Chemotherapy” obtained phase II clinical trial approval notices

03-21 18:45

Bailey Tianheng: The company has no deposits in Silicon Valley banks

03-21 14:57

Bailey Tianheng (688506): Preliminary nasopharyngeal cancer data are excellent and may add new indications

Core view: Incident: Recently, the “Notice on Voluntary Disclosure of Main Data of the BL-B01D1 (EGFR × HER3 Dual Antibody ADC) Project to Treat Locally Advanced or Metastatic Nasopharyngeal Cancer Indications” was released. As of March 10, there were 27 nasopharyngeal cancer subjects whose efficacy was evaluated at least once under all effective doses, with a median treatment line of 3. The objective remission rate (ORR) is 55.6%, the disease control rate (DCR) is 100%, and MPFS has not yet been reached; of these, phase II recommended dose (RP2D) 2.5m

03-13 07:33 · Researches

Bailey Tianheng (688506.SH) discloses the results of the BL-B01d1 nasopharyngeal cancer IB extended phase clinical trial

According to the Zhitong Finance App, Bailey Tianheng (688506.SH) announced that at present, BL-B01D1 (EGFR × HER3 dual antibody ADC) has carried out 5 phase Ia/Ib clinical studies, covering 16 types of tumors. Currently, more than 200 subjects with 12 types of tumors have been enrolled. Tumor evaluation data shows that BL-B01D1 has strong efficacy signals in all 12 types of tumors, and has good safety under the recommended phase II dose (RP2D). Among them, non-small cell lung cancer has shown a breakthrough curative effect of communicating with CDE to advance to registered clinical trials. The next step is not small

03-12 19:55

Bailey Tianheng: It is expected to open 3 registered clinics this year

02-28 14:44

Bailey Tianheng (688506.SH) earnings report: 2022 net loss of 286 million yuan

Glonghui, Feb. 27 丨 Bailey Tianheng (688506.SH) released its annual performance report for 2022, achieving total revenue of 703 million yuan, a year-on-year decrease of 11.73%; net profit attributable to parent company owners - 286 million yuan, a loss of 99.9913 million yuan for the same period last year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 340 million yuan, a loss of 154 million yuan for the same period last year; a basic loss of 0.79 yuan per share.

02-27 21:45

The shock in innovative drug concept stocks boosted Haichuang Pharmaceutical up more than 15%

02-02 09:59